No Data
This week in Hong Kong stocks, hot stocks include: the A-share IPO frenzy in Hong Kong! Contemporary Amperex Technology has risen over 22% since its listing this week, and Hengrui Pharmaceuticals jumped over 25% on its first day; the pharmaceutical Sector
ALI PICTURES has risen 55.56% this week, with stock prices reaching a three-year high! Citigroup states that the potential of IP Commodity has not been fully released.
Hong Kong stocks fluctuated | Giant Bio (02367) fell over 6%, the restructuring of collagen is controversial, and the company's 618 promotional campaign had a good start.
Giant Bioworks (02367) fell over 6%, as of the time of publication, it dropped by 6.15%, priced at 76.35 Hong Kong dollars, with a transaction volume of 0.908 billion Hong Kong dollars.
Hong Kong Stock Afternoon Review | The three major indices are rising, the Hang Seng TECH Index up 0.61%; Network Technology stocks and pharmaceutical stocks are climbing, Bilibili up over 5%, Hengrui Pharmaceuticals up over 30%.
The Network Technology stocks rose, with Bilibili-W up 5.42% and MEITUAN-W up 1.54%; the Battery stocks increased, BYD Company up 3.90% and Tianqi Lithium Corporation up 3.89%; the Autos stocks went up across the board, BRILLIANCE CHI up 5.31% and BYD Company up 3.90%;
PA GOODDOCTOR (01833.HK) has reached a strategic cooperation with Gaohe Pharmaceutical regarding the Kofumei brand.
PA GOODDOCTOR (01833.HK) has reached a strategic cooperation with Gaohuo Pharmaceutical regarding the collaboration on the Kefu Mei brand. This marks a new phase in PA GOODDOCTOR's strategic layout in the Medical and health equipment sector. Both parties will work together on Kefu Mei to promote the innovative application of recombinant collagen and related products, providing users with rich, convenient, intelligent, and more efficient health management solutions. As a core brand under Giant Biotechnology (02367.HK), Kefu Mei has focused on recombinant collagen as its core technological component since its establishment in 2011, aiming to address skin issues such as sensitivity, dermatitis, acne, and post-care for cosmetic projects.
Guotai Junan: New consumer representatives have emerged in various categories in the U.S. Bullish on growth opportunities under product innovation and the leverage of content e-commerce channels.
Due to characteristics such as strong self-care attributes, high sensitivity to changes in new demands, and a relatively decentralized landscape, the beauty and personal care brand has become a key player in the new consumer track. There are ongoing bullish outlooks on growth opportunities for new beauty consumption driven by product innovation combined with content e-commerce channel leverage.
Citibank initiates a "Buy" rating for Mao Geping (01318.HK) with a Target Price of 130 yuan.
Citi released a report covering Chinese local cosmetics company Mao Geping (01318.HK) for the first time, assigning a "Buy" rating with a Target Price of 130 Hong Kong dollars. The bank believes that Mao Geping has established a strong position in the high-end cosmetics market in China over more than 20 years and has continuously taken market share from international brands. Local competitors find it difficult to easily replicate its competitive advantages. Citi considers that Mao Geping's advantages include a strong founder IP and a professional artistic makeup brand positioning; enhancing professional reputation through makeup training institutions and a solid offline DTC store network to achieve cross-selling of high-end skincare products, increasing user stickiness. Citi expects Mao Geping to...
